Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combinations Key For Amgen’s Lumakras, But PD-1/L1 Data Held Until August

Combo Importance Increases With Sales Growth Slowing

Executive Summary

A World Conference on Lung Cancer abstract shows responses to Lumakras with a SHP2 inhibitor but closely watched results for anti-PD-1/L1 combinations are under embargo until the meeting next month.

You may also be interested in...



Can Amgen Balance Efficacy, Safety With KRAS/PD-1 Combination?

Data presented during the weekend at WCLC for Lumakras with Keytruda or Tecentriq raised questions about elevated liver toxicity and a lackluster response rate.

Finance Watch: Recent M&A Uptick Gives Biopharma A Needed Boost

Public Company Edition: William Blair analysts note that stock prices are rising due to a Q2 boost in dealmaking after a lull in Q1. Nevertheless, layoffs and portfolio prioritizations are ongoing, including at X4 Pharmaceuticals, but others have raised cash following good news, like Revolution Medicines.

Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field

Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients. 

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC146711

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel